UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 14, 2010 (January 13, 2010)
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Florida
(State or other jurisdiction
of incorporation)
|
|
000-33357
(Commission File Number)
|
|
65-0643773
(IRS Employer
Identification No.) |
| |
|
|
| 2 Snunit Street
|
|
20100 |
| Science Park, POB 455 |
|
|
| Carmiel, Israel |
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Ruled-2(b)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rulee-4(c)
|
On January 13, 2010, the Company issued a press release announcing that the Committee for Orphan
Medicinal Products (COMP) of the European Medicines Agency (EMEA), after reviewing all relevant
clinical data, has recommended that the European Commission grant orphan drug designation to
taliglucerase alfa, the Company’s proprietary plant cell expressed recombinant form of
glucocerebrosidase for the treatment of Gaucher disease. A copy of the press release is attached
hereto as Exhibit 99.1.
|
|
|
| Item 9.01. |
|
Financial Statements and Exhibits |
(d) Exhibits
| |
|
|
|
|
| |
99.1 |
|
|
Press release dated January 13, 2010. |
2